Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
288 Results for "
ATP-binding
" in MedChemExpress (MCE) Product Catalog:
Products (288)
288 Results for "ATP-binding" in MCE Product Catalog:
Cat. No.: HY-182383
CAS No.: 1209002-42-5
VMY-1-101 is a fluorescent cyclin-dependent kinase (CDK) inhibitor, with an excitation of 410 nm and emission of 512 nm. VMY-1-101 competitively inhibits ATP binding to CDKs. VMY-1-101 induces G2/M cell cycle arrest in human breast cancer cells. VMY-1-101 induces modest apoptosis in human breast cancer cells. VMY-1-101 blocks proliferation of human breast cancer cells, including multidrug resistance-positive cells, and is not a substrate for p-glycoprotein. VMY-1-101 localizes to the cytoplasm of human breast cancer cells. VMY-1-101 shows increased binding to human breast cancer tissue compared to fluorophore alone. VMY-1-101 can be used for the research of breast cancer .
Cat. No.: HY-183297
CDK4-IN-5 is a potent, orally active and selective CDK4 inhibitor. CDK4-IN-5 suppresses CDK4 expression and downregulates the CDK4/CyclinD1 complex. CDK4-IN-5 induces G0/G1 phase cell cycle arrest in bladder cancer cells via CyclinD1 expression suppression. CDK4-IN-5 selectively exerts activity against bladder cancer cells. CDK4-IN-5 can be used for the research of bladder cancer .
Cat. No.: HY-19989R
CAS No.: 115104-28-4
Synonyms: L-660711 (Standard)
Domaines de recherche:
MK-571 (Standard) is the analytical standard of MK-571 (HY-19989). This product is intended for research and analytical applications. MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .
Cat. No.: HY-N15301A
Target:
Domaines de recherche:
Cat. No.: HY-N9435R
CAS No.: 82373-95-3
Category:
Target:
Cat. No.: HY-W015329
CAS No.: 702-82-9
Target:
Domaines de recherche:
3-Amino-1-adamantanol is a p38α‑TAB1 interaction inhibitor. 3-Amino-1-adamantanol occupies the non-canonical docking site of p38α, inhibits the phosphorylation of TAB1 by activated pp38α, and disrupts the formation of the p38α‑TAB1 protein complex. 3-Amino-1-adamanol is applicable to research related to myocardial ischemic injury; it also serves as an intermediate for the synthesis of compounds such as Vildagliptin (HY-14291) .
Cat. No.: HY-184649
CAS No.: 2922859-30-9
CDK2-IN-60 is an orally active, ATP-competitive selective CDK2 inhibitor with a Ki of 77 pM. CDK2-IN-60 has high selectivity for both CDK4 and CDK1. CDK2-IN-60 blocks G1/S cell cycle progression to suppress proliferation of CCNE1-amplified tumor cells. CDK2-IN-60 serves as a lead chemical probe for investigating CCNE1-amplified cancers and CDK4/6 inhibitor-resistant HR-positive breast cancer .
Cat. No.: HY-110079R
CAS No.: 519178-28-0
Target:
Domaines de recherche:
TNP (Standard) is the analytical standard of TNP (HY-110079). This product is intended for research and analytical applications. TNP is a competitive, reversible inhibitor of IP6K1 and IP3K, with IC50s of 0.55 μM and 10.2 μM for IP6K1 and IP3K, respectively. TNP competitively binds to the ATP binding site of IP6K, inhibits the generation of 5-IP7, and thus relieves the inhibition of 5-IP7 on the AKT signaling pathway. TNP can enhance insulin sensitivity and promote thermogenesis in adipose tissue. TNP cannot effectively pass through the blood-brain barrier and is mainly used in the study of obesity, type 2 diabetes, and metabolic syndrome. However, TNP also inhibits CYP3A4 and may need further optimization .
Cat. No.: HY-150537
CAS No.: 2412364-73-7
Domaines de recherche:
AChE/GSK-3β-IN-1 (compound GT15) is a potent, dual AChE/GSK-3β inhibitor with IC50 values of 1.2, 149.8 and 22.4 nM for hAChE , hBChE and hGSK-3β, respectively. AChE/GSK-3β-IN-1 penetrates the blood-brain barrier (BBB). AChE/GSK-3β-IN-1 has high kinase selectivity profiles for the CMGC kinase family. AChE/GSK-3β-IN-1 occupies the ATP binding site of DYRK1A. AChE/GSK-3β-IN-1 inhibits ROS expression and reduces oxidative stress. AChE/GSK-3β-IN-1 can be used for Alzheimer’s disease research .
Cat. No.: HY-189286
Target:
Domaines de recherche:
Anticancer agent-364 is a phenylalanine-derived hydrazone heterocyclic compound that exhibits selective cytotoxicity against NSCLC lung cancer cells. Anticancer agent-364 inhibits VEGF-A, VEGFR-1, and VEGFR-2, increases caspase-3/7, caspase-8, and caspase-9 activity, and induces apoptosis. Anticancer agent-364 can be used for research on non-small cell lung cancer .
Cat. No.: HY-W020111
CAS No.: 837-52-5
Target:
Domaines de recherche:
7-Chloro-4-(piperazin-1-yl) quinoline is a quinoline-class synthetic intermediate that is used in organic synthesis-related research .
Cat. No.: HY-111250
CAS No.: 871026-18-5
SYR127063 is a potent and selective human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor with an IC50 of 11 nM. SYR127063 binds to the active site of the HER2 kinase domain in an ATP-competitive manner, thereby preventing the formation of the conserved salt bridge required for kinase activation. SYR127063 can be used in research related to breast cancer, ovarian cancer and gastric cancer .
Cat. No.: HY-189237
KIT/PDGFRA-IN-2 is a tyrosine kinase inhibitor targeting KIT and PDGFRA. KIT/PDGFRA-IN-2 inhibits the downstream signaling pathways of PDGFRA mutants, including the phosphorylation of AKT, MAPK and S6. KIT/PDGFRA-IN-2 can be used in the research of gastrointestinal stromal tumors .
Cat. No.: HY-184940
Target:
Domaines de recherche:
BTK-IN-50 is a covalent BTK inhibitor with an IC50 of 6 nM. BTK-IN-50 blocks collagen-induced platelet aggregation by inhibiting the GPVI-mediated BTK-PLCγ2-PKC signaling cascade, and attenuates CRP-XL-induced phosphorylation of BTK, PLCγ2 and PKC substrates in platelets. BTK-IN-50 can be used for research related to thrombosis .
Cat. No.: HY-W010076
CAS No.: 2150-47-2
Methyl 2,4-dihydroxybenzoate is an antifungal agent and plant defense activator. Methyl 2,4-dihydroxybenzoate disrupts the fungal antioxidant system, induces oxidative stress, interferes with N-glycosylation and protein synthesis, inhibits energy metabolism, and impairs transport function. Methyl 2,4-dihydroxybenzoate exhibits potent antifungal activity against the causal agent of banana Panama disease (Fusarium oxysporum f. sp. cubense) . Methyl 2,4-dihydroxybenzoate can also serve as a cosmetic raw material and is used in the synthesis of fine chemical raw materials. Methyl 2,4-dihydroxybenzoate is applicable to research related to Panama disease (Fusarium wilt) .
Cat. No.: HY-13752
CAS No.: 1118915-78-8
STA-1474 is an orally active and highly selective HSP90 inhibitor, as well as a phosphate prodrug of the HSP90 inhibitor STA-9090 (HY-15205). STA-1474 disrupts the chaperone function of HSP90 and promotes the degradation of client proteins. STA-1474 inhibits the phosphorylation of Met, Akt and STAT3, thereby blocking related signaling pathways. STA-1474 induces apoptosis and inhibits proliferation of osteosarcoma cells, and triggers the up-regulation of HSP70 and HSP90. STA-1474 induces tumor regression and caspase-3 activation in mouse osteosarcoma xenograft models. STA-1474 can be used in the research of osteosarcoma .
Cat. No.: HY-13752B
CAS No.: 1402907-09-8
STA-1474 sodium is an orally active and highly selective HSP90 inhibitor, as well as a phosphate prodrug of the HSP90 inhibitor STA-9090 (HY-15205). STA-1474 sodium disrupts the chaperone function of HSP90 and promotes the degradation of client proteins. STA-1474 sodium inhibits the phosphorylation of Met, Akt and STAT3, thereby blocking related signaling pathways. STA-1474 sodium induces apoptosis and inhibits proliferation of osteosarcoma cells, and triggers the up-regulation of HSP70 and HSP90. STA-1474 sodium induces tumor regression and caspase-3 activation in mouse osteosarcoma xenograft models. STA-1474 sodium can be used in the research of osteosarcoma .
Cat. No.: HY-183311
Target:
Domaines de recherche:
EGFR-IN-211 is a EGFR inhibitor with an IC50 of 0.131 μM. EGFR-IN-211 induces cell cycle arrest and apoptosis, and inhibits DNA synthesis and cell division. EGFR-IN-211 can be used in research related to cancers such as colorectal cancer and melanoma .
Cat. No.: HY-182073
EGFR-IN-207 (Compound 5h) is an epidermal growth factor receptor (EGFR) kinase inhibitor with an IC50 of 0.21 μM. EGFR-IN-207 induces cell cycle arrest at the Sub-G1 phase and promotes Apoptosis. EGFR-IN-207 exhibits anticancer activity against lung cancer. EGFR-IN-207 shows extremely low toxicity in non-cancerous cell lines. EGFR-IN-207 can be used in lung cancer-related research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
